tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Neumora Therapeutics reports Q2 EPS (33c), consensus (37c)
PremiumThe FlyNeumora Therapeutics reports Q2 EPS (33c), consensus (37c)
26d ago
Neumora Therapeutics price target raised to $5 from $4 at Mizuho
Premium
The Fly
Neumora Therapeutics price target raised to $5 from $4 at Mizuho
2M ago
Neumora Therapeutics’ Promising M4 PAM Program Drives Buy Rating with $18 Price Target
Premium
Ratings
Neumora Therapeutics’ Promising M4 PAM Program Drives Buy Rating with $18 Price Target
2M ago
Neumora Therapeutics, Inc.: Strengthened Financial Position and Strategic Operational Enhancements Drive Buy Rating
PremiumRatingsNeumora Therapeutics, Inc.: Strengthened Financial Position and Strategic Operational Enhancements Drive Buy Rating
4M ago
Strategic Developments and Long-Term Growth Prospects for Neumora Therapeutics Amid Financial Stability Enhancements
Premium
Ratings
Strategic Developments and Long-Term Growth Prospects for Neumora Therapeutics Amid Financial Stability Enhancements
4M ago
Neumora Therapeutics Reports Q1 2025 Financial Results
Premium
Company Announcements
Neumora Therapeutics Reports Q1 2025 Financial Results
4M ago
Tesla reports deliveries miss, Nintendo says Switch 2 out in June: Morning Buzz
PremiumThe FlyTesla reports deliveries miss, Nintendo says Switch 2 out in June: Morning Buzz
5M ago
Neumora Therapeutics, Inc. Faces Setbacks with Delayed MDD Program and Discontinued Bipolar Depression Study
Premium
Ratings
Neumora Therapeutics, Inc. Faces Setbacks with Delayed MDD Program and Discontinued Bipolar Depression Study
5M ago
Neumora Therapeutics downgraded to Underperform from Buy at BofA
Premium
The Fly
Neumora Therapeutics downgraded to Underperform from Buy at BofA
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100